The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Advancements in the treatment of biliary tract cancers
Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the latest developments in the management of biliary tract cancers, including the incorporation of circulating tumor DNA (ctDNA) in the prognostication of biliary tract cancers. Prof. Abou-Alfa additionally highlights the efficacy of gemcitabine and cisplatin with durvalumab as a treatment regimen. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
